Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year
© Schwabe / Paul Epp

Tuesday, October 6, 2026

Tobias Boldt to become Chief Commercial Officer at Schwabe in 2027

Schwabe Group is preparing a change in its commercial leadership. Tobias Boldt is set to join the Karlsruhe-based OTC and consumer health company as Chief Commercial Officer on 1 April 2027.

Boldt will move from Bayer, where he most recently served as Cluster Head Consumer Health Germany & Austria, overseeing the OTC business in both markets. He also led Natsana, a direct-to-consumer business for nutritional supplements within the Bayer environment.

Succession to Anke Balzer

At Schwabe, Boldt will succeed Dr. Anke Balzer. She has held the Chief Commercial Officer role since 2014 and plans to devote more time to her family. CEO Olaf Schwabe credited her with shaping the group’s commercial strategy and strengthening the regional setup of the business.

The appointment is relevant for Schwabe because the company operates in categories where brand management, pharmacy sales, digital channels and direct consumer access are becoming increasingly connected. Its portfolio includes OTC brands such as Lasea, Umckaloabo, Tebonin and Carmenthin.

Background in OTC, omnichannel and DTC

Boldt has spent his career to date at Bayer. He joined the Leverkusen-based company in 1998 and later held a range of national and international roles across Animal Health and Consumer Health. His assignments included positions in the Philippines and Poland. He took responsibility for Consumer Health in Germany and Austria in 2019.

In his latest Bayer role, Boldt focused on advancing the OTC business across channels. His remit included omnichannel transformation, data-based steering models and initiatives to improve growth and profitability. In 2025, the business also expanded through the acquisition of HiDoc Technologies, adding Bayer’s first digital health application for irritable bowel syndrome.

As CEO of Natsana, Boldt was involved in acquisitions, integration work and the economic repositioning of the business. He also worked on building a scalable direct-to-consumer platform for Europe and China, including a presence in major online channels such as Amazon.

Strategic context for Schwabe

The appointment comes as Schwabe broadens its activities beyond traditional OTC structures. In summer 2026, the group announced a majority stake in Hydraid, a Munich-based start-up focused on functional sports hydration and electrolytes. In May 2026, Schwabe made a strategic investment in Berlin-based digital health company Synaptikon, which operates the DiGA NeuroNation Med. In spring 2025, the group increased its stake in Braineffect, a Berlin-based DTC brand for nutritional supplements and functional foods.

For pharma and healthcare marketing executives, the move reflects a wider market shift. OTC companies are increasingly combining established brands with digital services, data-driven commercial models and more direct consumer relationships. Boldt’s background aligns closely with these priorities.

Advertisement

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • 8awake
  • MINTT Digital
  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

  • MINTT Digital

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.